Comparison of effectiveness and safety of three different antithrombotic regimens (bivalirudin, eptifibatide, and heparin) in preventing myocardial ischemia during percutaneous coronary intervention

被引：12

作者：

Wolfram, R ^{[1
]}

Leborgne, L ^{[1
]}

Cheneau, E ^{[1
]}

Pinnow, EE ^{[1
]}

Canos, DA ^{[1
]}

Hellinga, D ^{[1
]}

Satler, LF ^{[1
]}

Pichard, AD ^{[1
]}

Kent, KM ^{[1
]}

Waksman, R ^{[1
]}

机构：

[1] Washington Hosp Ctr, Washington Canc Ctr, Div Cardiol, Cardiovasc Res Inst, Washington, DC 20010 USA

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2003年 / 92卷 / 09期

关键词：

D O I：

10.1016/j.amjcard.2003.06.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The aim of this retrospective, observational analysis was to compare,the efficacy and safety of 3 antithrombotic regimens: bivalirudin, eptifibatide plus heparin, and heparin alone, with emphasis on preventing interventional procedural creatinine kinase-MB fraction (CK-MB) release, and consequently, myocardial necrosis. (C) 2003 by Excerpta Medica, Inc.

引用

页码：1080 / 1083

页数：4

共 20 条

[1]

Adgey AAJ, 1998, EUR HEART J, V19, pD10

[2]

Bittl J A, 2000, J Invasive Cardiol, V12 Suppl F, p2F

[3] Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study [J].

Bittl, JA ;

Chaitman, BR ;

Feit, F ;

Kimball, W ;

Topol, EJ .

AMERICAN HEART JOURNAL, 2001, 142 (06) :952-959

[4] Effect of eptifibatide on angiographic complications during percutaneous coronary intervention in the IMPACT-(Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis) II trial [J].

Blankenship, JC ;

Sigmon, KN ;

Pieper, KS ;

O'Shea, C ;

Tardiff, BE ;

Tcheng, JE .

AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (09) :969-973

[5] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[6] UNSTABLE ANGINA WITH FATAL OUTCOME - DYNAMIC CORONARY THROMBOSIS LEADING TO INFARCTION AND OR SUDDEN-DEATH - AUTOPSY EVIDENCE OF RECURRENT MURAL THROMBOSIS WITH PERIPHERAL EMBOLIZATION CULMINATING IN TOTAL VASCULAR OCCLUSION [J].

FALK, E .

CIRCULATION, 1985, 71 (04) :699-708

[7]

HIRSH J, 1991, NEW ENGL J MED, V324, P1565

[8] HEPARIN - MECHANISM OF ACTION, PHARMACOKINETICS, DOSING CONSIDERATIONS, MONITORING, EFFICACY, AND SAFETY [J].

HIRSH, J ;

RASCHKE, R ;

WARKENTIN, TE ;

DALEN, JE ;

DEYKIN, D ;

POLLER, L .

CHEST, 1995, 108 (04) :S258-S275

[9] Prognostic implication of creatine kinase elevation following elective coronary artery interventions [J].

Kong, TQ ;

Davidson, CJ ;

Meyers, SN ;

Tauke, JT ;

Parker, MA ;

Bonow, RO .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (06) :461-466

[10] Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention - REPLACE-2 Randomized Trial [J].

Lincoff, AM ;

Bittl, JA ;

Harrington, RA ;

Feit, F ;

Kleiman, NS ;

Jackman, JD ;

Sarembock, IJ ;

Cohen, DJ ;

Spriggs, D ;

Ebrahimi, R ;

Keren, G ;

Carr, J ;

Cohen, EA ;

Betriu, A ;

Desmet, W ;

Kereiakes, DJ ;

Rutsch, W ;

Wilcox, RG ;

de Feyter, PJ ;

Vahanian, A ;

Topol, EJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (07) :853-863

← 1 2 →